🕵️ Nuvectis Pharma, Inc. ($NVCT)
SEC insider & ownership activity, last 12 months · CIK 1875558 · every row links its SEC filing
Over the last 12 months insiders bought $2.3M with no open-market selling against it. Mosseri Marlio Charles bought $1.9M (Oct–Jun). No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
4 buyers, $2.3M (8 lots) · 0 sellers, $0 (0 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Mosseri Marlio Charles | 4 | $1.9M | 0 | – | Jun 30, 2026 |
| Bentsur Ron | 2 | $279K | 0 | – | Jun 30, 2026 |
| Sanchez Juan | 1 | $75K | 0 | – | Nov 5, 2025 |
| Matthew L. Kaplan | 1 | $64K | 0 | – | Nov 5, 2025 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Soleus Capital Management, L.P. | 5.1% | 13G | Aug 6, 2026 | filing ↗ | |
| Soleus GP, LLC | 5.1% | 13G | Aug 6, 2026 | filing ↗ | |
| Levy Guy | 5.1% | 13G | Aug 6, 2026 | filing ↗ |
Planned insider sales (Form 144)
No sale notices filed in the last 12 months.
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Earnings (2.02) | Aug 4, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 4, 2026 | filing ↗ |
| Other events (8.01) | Jul 20, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 20, 2026 | filing ↗ |
| Material agreement (1.01) | Jun 29, 2026 | filing ↗ |
| Other events (8.01) | Jun 29, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 29, 2026 | filing ↗ |
| Other events (8.01) | Jun 29, 2026 | filing ↗ |
| Material agreement (1.01) | Jun 22, 2026 | filing ↗ |
| Other events (8.01) | Jun 22, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 22, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 11, 2026 | filing ↗ |
| Earnings (2.02) | May 5, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 5, 2026 | filing ↗ |
| Earnings (2.02) | Feb 11, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Feb 11, 2026 | filing ↗ |
| Earnings (2.02) | Nov 4, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 4, 2025 | filing ↗ |
| Officer/director changes (5.02) | Sep 22, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Sep 22, 2025 | filing ↗ |